Core Insights - Ginkgo Bioworks has partnered with Deep Origin on a 4.5-year project funded by ARPA-H to develop a computational platform for drug safety [1][4] - The collaboration, named PREDICTS, aims to enhance pharmacological research through digital integration and clinical trial simulation [1][4] Company Overview - Ginkgo Bioworks specializes in engineering biology and offers customizable R&D solutions, including protein engineering and nucleic acid design [6] - The company utilizes its 'Datapoints' platform to generate large, structured datasets for AI model training, focusing on drug safety and efficacy [2][4] Project Details - The PREDICTS project will leverage Ginkgo's high-throughput capabilities to create detailed models of cellular responses to drug treatments [3][4] - The initiative will include various readouts such as cell type-specific toxicity endpoints and DRUG-seq transcriptomics [2] Strategic Importance - This partnership highlights Ginkgo's commitment to interdisciplinary collaboration and its expertise in generating large datasets for drug development [4] - The collaboration is expected to push the boundaries of multi-omics data generation, transforming drug discovery processes [4]